Zanubritnib and Anti-MAG Neuropathy | MicrobiomeTrials← Back to trialsNCT07392229
Zanubritnib and Anti-MAG Neuropathy
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-03-24Est. Completion: 2031-03
Enrollment target: 50 participants Locations- CTU Ematologia, Grande Ospedale Metropolitano Niguarda, Milan, Milan, Italy
- UOC Ematologia, Azienda Ospedale Università Padova, Padova, PD, Italy
- SC UCO Ematologia, Ospedale Maggiore di Trieste, Trieste, Trieste, Italy
Other microbiome trials you might be interested in
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The use of neuroimaging in the evaluation of neuromuscular pathologies is a promising and rapidly expandinf field. Among…
Nice, FranceCompleted Jan 1, 2022
Demyelinating Sensorimotor Neuropathy
Anti-myelin-associated glycoprotein (MAG) is a rare autoimmune disorder of the peripheral nerves that presents with weak…
Ann Arbor, United StatesCompleted Feb 28, 2022